Tactile Systems (TCMD) Q4 2024 earnings summary

Executive summary

• Q4 revenue reached $85.6 million, up 10.2% year-over-year, with full-year revenue at $293 million, a 6.8%-7% annual increase.

• Lymphedema product sales grew 11% year-over-year in Q4, with sequential growth of 18.1%.

• Airway clearance (Afflovest) sales rose 3.8%-4% year-over-year in Q4.

• Served over 79,000 patients in 2024, with strong commercial execution and technology investments.

• Ended 2024 with $94.4 million in cash, up from $61.0 million at 2023 year-end.

Financial highlights

• Q4 gross margin was 75.2%, up from 72.1% in Q4 2023, with full-year gross margin at 74%.

• Q4 operating expenses increased 17.3% to $51.9 million, mainly due to sales, marketing, and tech investments.

• Q4 net income was $9.7 million (40 cents per diluted share), up 18.3% year-over-year.

• Q4 adjusted EBITDA was $16.2 million, up 5%-5.5% year-over-year; full-year adjusted EBITDA was $37.1 million, up 25%.

• Operating cash flow for 2024 was $40.7 million, up from $35.9 million in 2023.

Outlook and guidance

• 2025 revenue expected between $316-$322 million, representing 8%-10% year-over-year growth.

• Lymphedema product line growth projected at 8%-10%; airway clearance at 6%-9%.

• GAAP gross margin for 2025 expected at ~74%; operating expenses to rise mid-double digits.

• Adjusted EBITDA guidance for 2025 is $35-$37 million.

• Growth expected to accelerate in the second half of 2025 as strategic initiatives gain traction.